Oncocyte Corporation - Common Shares, No Par Value (OCX)

Historical Holders from Q4 2015 to Q2 2025

Type / Class
Equity / Common Shares, No Par Value
Symbol
OCX on Nasdaq
Shares outstanding
28,495,649
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Oncocyte Corporation - Common Shares, No Par Value (OCX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIO-RAD LABORATORIES, INC. 9.7% $6,578,506 2,764,078 BIO-RAD LABORATORIES, INC 10 Feb 2025
SMITH PATRICK W 10% $4,221,889 1,773,903 Patrick W. Smith 26 Dec 2024

Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q2 0 $0 -$126,921 0
2025 Q1 44,378 $126,921 -$7,722 286% 1
2024 Q4 47,078 $112,046 -$29,215 238% 1
2024 Q3 59,353 $169,156 -$3,224,887 285% 1
2024 Q2 1,152,395 $3,399,565 +$1,009,561 295% 2
2024 Q1 810,171 $2,373,801 -$46,191 293% 2
2023 Q4 825,936 $2,049,754 -$20,365 249% 2
2023 Q3 833,802 $2,716,547 -$68,394,979 320% 2
2023 Q2 91,821,550 $21,118,229 +$8,243,515 23% 45
2023 Q1 55,657,631 $19,725,177 -$1,788,823 35.44% 51
2022 Q4 60,665,357 $19,466,217 -$2,586,310 32.09% 53
2022 Q3 66,111,852 $48,283,884 -$1,937,448 73.06% 53
2022 Q2 66,176,797 $59,540,567 +$14,467,659 89.99% 60
2022 Q1 54,291,633 $80,994,102 -$2,237,000 149% 73
2021 Q4 55,296,502 $119,875,059 -$4,924,091 216.97% 81
2021 Q3 56,483,284 $201,583,971 -$4,558,137 356.04% 92
2021 Q2 56,557,145 $324,629,337 +$10,095,420 574% 88
2021 Q1 54,522,186 $282,963,492 +$107,506,903 519% 83
2020 Q4 30,115,573 $71,976,746 +$2,784,833 239% 55
2020 Q3 31,214,379 $43,380,422 -$4,514,859 138.96% 53
2020 Q2 31,013,341 $59,278,536 +$8,523,033 191.08% 53
2020 Q1 26,139,779 $64,013,452 +$4,118,940 245% 49
2019 Q4 25,784,938 $57,995,716 +$15,543,938 224.83% 49
2019 Q3 18,823,157 $39,524,066 +$5,931,727 209.92% 50
2019 Q2 15,951,323 $39,736,182 -$2,945,189 249.25% 46
2019 Q1 16,114,855 $63,650,620 +$30,828,789 394.99% 44
2018 Q4 8,316,794 $11,476,217 -$814,785 137.95% 14
2018 Q3 8,717,247 $21,791,392 -$155,391 249.68% 19
2018 Q2 8,777,995 $22,384,400 +$410,960 255% 23
2018 Q1 8,632,498 $18,126,749 +$8,211,937 209.78% 26
2017 Q4 4,673,761 $21,733,469 +$1,173,693 464.99% 30
2017 Q3 4,408,219 $33,282,650 +$3,967,325 755% 24
2017 Q2 3,898,809 $20,268,960 +$545,425 519.39% 28
2017 Q1 3,774,995 $22,465,000 +$4,356,437 594.62% 24
2016 Q4 3,125,222 $22,031,000 +$342,648 705% 25
2016 Q3 3,076,034 $15,501,000 +$7,602,924 503.52% 17
2016 Q2 1,579,787 $5,624,178 -$381,956 356.01% 22
2016 Q1 1,662,462 $7,661,812 +$2,620,363 461.28% 28
2015 Q4 206 $1,000 +$1,000 485.44% 1